DCB can maximize the patency rate of blood vessels on the basis of intraluminal DA. DA+DCB treatment is effective and safe \[8\], and the advantages of DA and DCB in the treatment of severe calcification and occlusive disease across joints and lower extremities have been confirmed. The combined application of DA and DCB in the treatment of peripheral arterial disease has a good early and mid-term effect. Konstantinos et al. reported that DARRT has a higher first-phase patency rate compared with DCB. A retrospective study by Sebastian et al. showed that compared with PTA after DA, the combination of DA and DCB has a better event-free survival rate after 12 months of follow-up. Therefore, DA combined with DCB therapy may be one of the best and most promising methods for the treatment of lower extremity ASO.
Study Type
OBSERVATIONAL
Enrollment
240
Directly remove the diseased plaque in the blood vessel to increase the effective lumen in the blood vessel
Paclitaxel
the Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
RECRUITINGPrimary vascular patency rate
Free-Target lesion reconstruction rate(F-TLR)at 24 months after operation
Time frame: 24 months
Major adverse event
MAE within 24 months after surgery
Time frame: 24 months
Quality of life assessment
Quality of life assessment (VAS-QOL) after discharge, 1, 3, 6, 12, and 24 months after operation
Time frame: 24 months
ABI
Ankle-brachial index (ABI) at discharge, 1, 3, 6, 12, and 24 months after operation
Time frame: 24 months
Rutherford classification
Discharge, 1, 3, 6, 12, and 24 months after the Rutherford classification
Time frame: 24 months
TLR
The incidence of TLR after discharge, 1, 3, 6, 12, and 24 months
Time frame: 24 months
TVR
The incidence of TVR after discharge, 1, 3, 6, 12, and 24 months
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.